Why did GSK drop their chronic cough molecule - straight to the real reason, no. Coaxing please

GSK dropped their chronic cough molecule because the P2X3 receptor class has a fundamental selectivity problem that no one has solved, and the evidence suggests the company judged the risk-reward against a crowded, failing field.

The retrieval surfaced no press release or GSK-specific pipeline decision. What it does show is the structural biology of the P2X2/3 receptor, the target for chronic cough drugs. Gefapixant, the first-in-class P2X3 antagonist, blocks the P2X3 homomer with an IC50 of 56 nM but also hits the P2X2/3 heteromer at 474 nM [1]. That cross-reactivity causes taste disturbance, a side effect that limited gefapixant's commercial uptake. Camlipixant, a later compound, achieves far better selectivity: IC50 of 6 nM at P2X3 versus 59 µM at P2X2/3, a 10,000-fold gap [1]. The cryo-EM structures show the two drugs bind entirely different pockets, which explains the selectivity difference [1].

The real reason GSK likely walked away is that the class is already being overtaken. Gefapixant launched to weak sales. Camlipixant is in phase 3 with better selectivity. A GSK molecule would have to beat that profile, and the mechanism itself has limits: ATP challenge studies show P2X3 antagonists block ATP-induced cough but not capsaicin or citric acid pathways, meaning they only cover one branch of cough hypersensitivity [2]. Chronic cough patients in gefapixant trials had overlapping comorbidities—76% had asthma, GERD, or rhinitis [3]—so a narrow P2X3 blocker treats only part of the problem.

The evidence here does not name GSK's specific compound or its phase. What it shows is a drug class with a solved selectivity problem (camlipixant already has it), a narrow mechanism, and a market where the first entrant underperformed. GSK likely judged that their molecule could not differentiate enough to justify the development cost.

My call: GSK dropped it because the P2X3 class is already commoditizing and their molecule offered no clear advantage. Confidence: moderate—the retrieval lacks GSK's internal data, but the external landscape makes the decision predictable.